Smy Laura, Shaw Kaitlyn, Amstutz Ursula, Smith Anne, Berger Howard, Carleton Bruce, Koren Gideon
Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON, Canada.
Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
BMC Pregnancy Childbirth. 2016 Jul 20;16(1):176. doi: 10.1186/s12884-016-0962-4.
Cortisol is a hormone involved in many physiological functions including fetal maturation and epigenetic programming during pregnancy. This study aimed to use hair cortisol as a biomarker of chronic inhaled corticosteroid (ICS) exposure and assess the potential effects of asthma on the hypothalamic-pituitary-adrenal (HPA) axis in pregnant women. We hypothesized that pregnant women with asthma treated with ICS would exhibit lower hair cortisol concentrations, indicative of adrenal suppression, compared to women with asthma not using ICS and women who do not have asthma.
We performed an observational retrospective cohort study. Hair samples were analyzed from pregnant women with asthma, with (n = 56) and without (n = 31) ICS treatment, and pregnant women without asthma (n = 31). Hair samples were segmented based on the growth rate of 1 cm/month and analyzed by enzyme immunoassay to provide cortisol concentrations corresponding to preconception, trimesters 1-3, and postpartum. Hair cortisol concentrations were compared within and among the groups using non-parametric statistical tests.
Hair cortisol concentrations increased across trimesters for all three groups, but this increase was dampened in women with asthma (P = 0.03 for Controls vs. ICS Treated and Controls vs. No ICS). ICS Treated women taking more than five doses per week had hair cortisol concentrations 47 % lower in third trimester than Controls. Linear regression of the third trimester hair cortisol results identified asthma as a significant factor when comparing consistent ICS use or asthma as the predictor (F(1, 25) = 9.7, P = 0.005, R(2) adj = 0.257).
Hair cortisol successfully showed the expected change in cortisol over the course of pregnancy and may be a useful biomarker of HPA axis function in pregnant women with asthma. The potential impact of decreased maternal cortisol in women with asthma on perinatal outcomes remains to be determined.
皮质醇是一种参与多种生理功能的激素,包括胎儿成熟和孕期的表观遗传编程。本研究旨在将头发皮质醇用作慢性吸入性糖皮质激素(ICS)暴露的生物标志物,并评估哮喘对孕妇下丘脑-垂体-肾上腺(HPA)轴的潜在影响。我们假设,与未使用ICS的哮喘女性和无哮喘女性相比,接受ICS治疗的哮喘孕妇的头发皮质醇浓度会更低,这表明存在肾上腺抑制。
我们进行了一项观察性回顾性队列研究。分析了哮喘孕妇(使用ICS的n = 56例,未使用ICS的n = 31例)和无哮喘孕妇(n = 31例)的头发样本。根据每月1厘米的生长速度对头发样本进行分段,并通过酶免疫测定法进行分析,以提供对应孕前、孕1 - 3期和产后的皮质醇浓度。使用非参数统计检验比较组内和组间的头发皮质醇浓度。
三组的头发皮质醇浓度在孕期均有升高,但哮喘女性的这种升高受到抑制(对照组与ICS治疗组比较,以及对照组与未使用ICS组比较,P = 0.03)。每周使用超过五剂ICS的治疗组女性在孕晚期的头发皮质醇浓度比对照组低47%。比较持续使用ICS或哮喘作为预测因素时,孕晚期头发皮质醇结果的线性回归确定哮喘是一个显著因素(F(1, 25) = 9.7,P = 0.005,调整后R(2) = 0.257)。
头发皮质醇成功显示了孕期皮质醇的预期变化,可能是哮喘孕妇HPA轴功能的有用生物标志物。哮喘女性母体皮质醇降低对围产期结局的潜在影响仍有待确定。